Metastatic Melanoma
Conditions
Brief summary
Combination therapy is becoming more and more general in the treatment of oncological diseases. In this clinical trial combination the standard immunotherapeutic treatment; the programmed death 1 (PD-1) regulatory antibody Nivolumab and a peptide vaccine consisting of programmed death ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase (IDO) peptides will be tested in patients with metastatic melanoma. Patients will be treated with Nivolumab every second week as long as there is clinical benefit. The PD-L1/IDO peptide vaccine is given from start of Nivolumab and every second week for the first 6 vaccines and thereafter every fourth week up to 1 year.
Detailed description
Background: Huge advances have been made in the treatment of metastatic melanoma (MM) the past 5 years. Especially immunotherapy has shown promising results. Cancer cells are naturally attacked by cells of the immune system, but can induce a state of tolerance whereby they escape from immune attack. This escape is brought about by many mechanisms. An important one is the programmed death pathway (PD-1/PD-L1). PD-L1 is commonly overexpressed on cancer cells. Interaction of PD-1 on activated T cells and PD-L1 on cancer cells lead to inhibition of the cytotoxic T cells. Another important mechanism is through overexpression of the metabolic enzyme IDO on cancer cells. Activation of IDO also inhibits cytotoxic T cells. Investigators have recently identified spontaneous T cell reactivity against PD-L1 and IDO in the tumor microenvironment and in the peripheral blood of patients with MM and healthy donors. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro.. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. Due to distinct mechanisms of action, the combination of treatment with a monoclonal antibody targeting PD-1 (Nivolumab) and a vaccine with peptides against PD-L1 and IDO may have a synergistic effect. Investigators have previously reported a phase I trial where, the IDO peptide was tested in 15 patients with MM in combination with Ipilimumab, and no grade 3-4 toxicity was seen. The PD-L1 peptide is currently being tested in a first-in-man study in patients with multiple myeloma. Methods: A two-step clinical phase I/II trial design will be used, starting out with a pilot study including 6 patients with MM to test feasibility and tolerability. If the treatment is found feasible the study will be extended to a phase II study with 24 patients. The objective is to describe anti-tumor immune responses and objective responses using RECIST 1.1. Patients will be treated with Nivolumab in accordance with standard regimen, which involves outpatient IV infusions every second week as long as there is clinical benefit. The PD-L1/IDO peptide vaccine is given from start of Nivolumab and every second week for the first 6 vaccines and thereafter every fourth week up to 1 year. 15 vaccines will be administered in total. Patients will be followed with clinical controls and diagnostic imaging every 12 weeks. Patients who receive all vaccines will have follow up after 3 and 6 months in parallel with standard of care treatment for Nivolumab.
Interventions
DRUGNivolumab
Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
BIOLOGICALPD-L1/IDO peptide vaccine
The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
Sponsors
Inge Marie Svane
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 2. The patient has unrespectable or metastatic melanoma with progressive, persistent or recurrent disease on or following treatment with standard of care agents 3. Patients belonging to one of the following patient groups will be enrolled: Cohort A: Anti PD-1/PD-L1 naïve patients (30 patients). The patient is a candidate for Nivolumab monotherapy. Prior anti-PD-1/anti-PD-L1 antibody treatment is not allowed. OR Cohort B: Extension cohort (10 patients). Progressive disease ON anti-PD-1 monotherapy.Subjects should not have experienced serious and/or life-threatening toxicity to antibody therapy. OR Cohort C: Extension cohort (10 patients). Progressive disease during follow up OFF anti-PD-1 after clinical benefit (SD/PR/CR) on anti-PD-1 therapy. Subjects should not have discontinued antibody therapy due to serious and/or lifethreatening toxicity 4. At least one measurable parameter according to RECIST 1.1. 5. The patient has an ECOG performance status of 0 or 1 6. The patient is a female of childbearing potential with negative pregnancy test 7. For women: Agreement to use contraceptive methods with a failure rate of \< 1 % per year during the treatment period and for at least 120 days after the treatment 8. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm 9. The patient has met the following hematological and biochemical criteria: 1. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases 2. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN 3. Serum creatinine ≤1,5 X ULN 4. ANC (Absolute Neutrophil Count) ≥1,000/mcL 5. Platelets ≥ 75,000 /mcL 6. Hemoglobin ≥ 9 g/dL eller ≥ 5.6 mmol/L 10. Signed declaration of content after oral and written information about the protocol.
Exclusion criteria
1. The patient has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radioactive or biological cancer therapy 2. The patient has not recovered from surgery or is less than 4 weeks from major surgery 3. The patient has a history of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering 4. The patient is expected to require any other form of systemic antineoplastic therapy while receiving the treatment 5. The patient has a history of severe clinical autoimmune disease 6. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C 7. The patient requires systemic steroids for management of immune-related adverse events experienced on another immunotherapy 8. The patient has active CNS metastases and/or carcinomatous meningitis. However, patients with subclinical brain metastases \< 1 cm can be included (maximum of 4 metastases \< 1 cm). (Patients with previously treated brain metastases may participate provided they are clinically stable. Patients with untreated brain metastasis will be excluded) 9. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders) 10. The patient is pregnant or breastfeeding 11. The patient is unable to voluntarily agree to participate by signed informed consent or assent 12. The patient has an active infection requiring systemic therapy 13. The patient has received a live virus vaccine within 30 days of planned start of therapy 14. Known side effects to Montanide ISA-51 15. Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus 16. Concurrent treatment with other experimental drugs 17. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc. 18. Severe allergy or anaphylactic reactions earlier in life
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | 0 - 75 weeks | Determine the safety of the combination therapy of Nivolumab and the PD-L1/IDO peptide vaccine for patients with metastatic melanoma by reporting adverse events according to CTCAE v. 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Vaccine-specific Responses in Peripheral Blood Mononuclear Cells (PBMCs) | At baseline and up to 24 months after inclusion | Number of patients with a significant increase of vaccine-specific T cells in the blood during vaccination, assessed by the presence of vaccine-specific responses in peripheral blood mononuclear cells (PBMCs) before, on and after vaccination using a modified interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT) assay. |
| Objective Response Rate | The patients were evaluated every 12 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 58 months | Clinical response will be evaluated by RECIST and PERCIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET-CT scans: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Overall Survival | The patients were evaluated from the date of first study treatment until the date of death from any cause, assessed up to 58 months | Overall survival (OS) defined as the time from treatment until death or end of follow-up |
| Progression Free Survival | The patients were evaluated from date of first study treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 58 months | Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Countries
Denmark
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A Anti PD-1/PD-L1 naïve patients (30 patients). The patient is a candidate for Nivolumab monotherapy. Prior anti-PD-1/anti-PD-L1 antibody treatment is not allowed. | 30 |
| Arm B Extension cohort (10 patients). Progressive disease ON anti-PD-1 antibody monotherapy. Subjects should not have experienced serious and/or life-threatening toxicity to antibody therapy. | 14 |
| Arm C Extension cohort (10 patients). Progressive disease during follow up OFF anti-PD-1 after clinical benefit (SD/PR/CR) on anti-PD-1 antibody therapy. Subjects should not have discontinued antibody therapy due to serious and/or life-threatening toxicity | 4 |
| Total | 48 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 0 |
| Overall Study | included in another protocol | 0 | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Total | Arm B | Arm C | Arm A |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 35 Participants | 9 Participants | 3 Participants | 23 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants | 5 Participants | 1 Participants | 7 Participants |
| Race and Ethnicity Not Collected | 0 Participants | — | — | — |
| Region of Enrollment Denmark | 48 Participants | 14 Participants | 4 Participants | 30 Participants |
| Sex: Female, Male Female | 24 Participants | 8 Participants | 2 Participants | 14 Participants |
| Sex: Female, Male Male | 24 Participants | 6 Participants | 2 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 12 / 30 | 6 / 14 | 2 / 4 |
| other Total, other adverse events | 30 / 30 | 13 / 14 | 4 / 4 |
| serious Total, serious adverse events | 11 / 30 | 2 / 14 | 1 / 4 |
Outcome results
Primary
Number of Participants With Adverse Events
Determine the safety of the combination therapy of Nivolumab and the PD-L1/IDO peptide vaccine for patients with metastatic melanoma by reporting adverse events according to CTCAE v. 4.0.
Time frame: 0 - 75 weeks
Population: Adverse Events recorded for all patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A | Number of Participants With Adverse Events | 30 Participants |
| Arm B | Number of Participants With Adverse Events | 10 Participants |
| Arm C | Number of Participants With Adverse Events | 4 Participants |
Secondary
Evaluation of Vaccine-specific Responses in Peripheral Blood Mononuclear Cells (PBMCs)
Number of patients with a significant increase of vaccine-specific T cells in the blood during vaccination, assessed by the presence of vaccine-specific responses in peripheral blood mononuclear cells (PBMCs) before, on and after vaccination using a modified interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT) assay.
Time frame: At baseline and up to 24 months after inclusion
Population: Arm A: 30 patients had blood samples available for analysis Arm B: 6/10 patients had blood samples available for analysis Arm C: 1/4 patients had blood samples available for analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A | Evaluation of Vaccine-specific Responses in Peripheral Blood Mononuclear Cells (PBMCs) | 28 Participants |
| Arm B | Evaluation of Vaccine-specific Responses in Peripheral Blood Mononuclear Cells (PBMCs) | 2 Participants |
| Arm C | Evaluation of Vaccine-specific Responses in Peripheral Blood Mononuclear Cells (PBMCs) | 1 Participants |
Secondary
Objective Response Rate
Clinical response will be evaluated by RECIST and PERCIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET-CT scans: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: The patients were evaluated every 12 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 58 months
Population: Overall response rate (ORR)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A | Objective Response Rate | 24 Participants |
| Arm B | Objective Response Rate | 0 Participants |
| Arm C | Objective Response Rate | 2 Participants |
Secondary
Overall Survival
Overall survival (OS) defined as the time from treatment until death or end of follow-up
Time frame: The patients were evaluated from the date of first study treatment until the date of death from any cause, assessed up to 58 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A | Overall Survival | NA months |
| Arm B | Overall Survival | 16.7 months |
| Arm C | Overall Survival | NA months |
Secondary
Progression Free Survival
Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: The patients were evaluated from date of first study treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 58 months
Population: Only four of ten participants were treated in this cohort. The data was not analyzed due to early termination of the trial cohort
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A | Progression Free Survival | 25.5 months |
| Arm B | Progression Free Survival | 2.4 months |
| Arm C | Progression Free Survival | NA months |